JEMPERLI 500 mg concentrate for solution for infusion clinical trials
7 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma positive for PD-L1 expression and germline or somatic mutations in the HRR genes
This study looks at a new combination of two medicines, niraparib and dostarlimab, for people with a type of lung cancer called pleural mesothelioma. Researchers want to see if this treatment can stop the cancer from growing for longer periods.
For: NON SMALL CELL LUNG CANCER · PLEURAL MESOTHELIOMAItaly - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours
This study is looking at two new medicines, Zejula (niraparib) and JEMPERLI (dostarlimab), for children and young people with solid tumours that have come back or not responded to other treatments. The main goal is to find a safe dose and see if they work together.
For: Solid TumoursSpain · Germany · Czechia - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase I-II Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab in Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy. LiDer trial
This study is looking at a new combination treatment for advanced womb cancer that has come back or spread after previous chemotherapy. It aims to see how safe and effective lurbinectedin and dostarlimab are together in hopefully shrinking tumours.
For: Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based ChemotherapySpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
This study looks at new treatments for a type of lung cancer that has spread. It compares two different drug combinations, both including chemotherapy, to see which works better at shrinking tumours and helping people live longer. It's a key step in finding improved care.
For: Lung Cancer · Non-Small CellGermany · Romania · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors (NIRADO)
This study is testing two medicines, JEMPERLI and Zejula, together to see if they can help people with certain types of cancer. Doctors want to know how well this combination shrinks tumors and if it's safe to use. It's a next step in finding new cancer treatments.
For: DNA repair-deficient or platinum-sensitive solid tumorsFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)
This study is looking into a new treatment for children and young adults with certain types of cancer that haven't responded to other treatments. It will check how safe the new treatment is and if it helps shrink the tumours.
For: Relapsed/Refractory TumorsSpain · France · Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors
This study is testing new combinations of medicines for advanced solid cancers. It looks at how safe the treatments are and how well they shrink or control the cancer. The aim is to find better ways to treat these cancers.
For: Advanced solid tumorsItaly · France · Belgium